首页> 外文OA文献 >Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk.
【2h】

Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk.

机译:乳头抽吸液:一种有前途的非侵入性方法,可识别乳腺癌风险的细胞标志物。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To evaluate the feasibility of nipple aspiration and to identify intermediate markers of breast cancer risk, nipple aspirate fluid (NAF) was collected from 177 subjects using a modified breast pump. The first 33 subjects demonstrated that we could obtain NAF quickly, reliably and repeatedly. Specimens from the remaining 144 subjects were collected to evaluate promising cellular biomarkers. NAF was obtained in 167 out of 177 (94%) subjects overall and in 99% of the 144 most recent subjects. Sufficient NAF was obtained to evaluate cytology in 160 out of 167 (96%) cases and specimens were sufficiently cellular to analyse DNA markers in 53% of cases. Among the last 144 subjects, menopausal status did not influence the ability to obtain NAF. NAF cytology correlated with increased breast cancer risk (P = 0.002). Using computerized image analysis of NAF epithelial cells, DNA index (P = 0.0002), percentage of cells in G2M (P = 0.05) and percentage of cells with hypertetraploidy (P = 0.002) increased as cytology became more abnormal. Our data indicate that NAF can be obtained in essentially all eligible subjects; that breast epithelial cells are evaluable in > 95% of NAF samples for cytology and in over half of NAF samples for DNA index (ploidy) and cell cycle analysis; and that abnormal NAF cytology correlates with increased breast cancer risk. This suggests that biomarkers identified in nipple aspirate fluid may prove useful either as an adjunct to currently accepted breast cancer screening methods, or to evaluate response to a chemopreventive agent.
机译:为了评估乳头抽吸术的可行性并确定乳腺癌风险的中间标志物,使用改良的吸乳器从177名受试者中收集了乳头抽吸液(NAF)。前33名受试者证明我们可以快速,可靠且重复地获得NAF。收集了来自其余144名受试者的标本,以评估有前途的细胞生物标志物。在177名受试者中,有167名(94%)获得了NAF,在144名最新受试者中,有99%获得了NAF。在167例病例中,有160例(96%)获得了足够的NAF来评估细胞学,并且53%的样本具有足够的细胞分析DNA标记物的能力。在最后的144名受试者中,绝经状态不影响获得NAF的能力。 NAF细胞学检查与乳腺癌风险增加相关(P = 0.002)。使用计算机分析的NAF上皮细胞,DNA指数(P = 0.0002),G2M中的细胞百分比(P = 0.05)和具有超四倍体性的细胞百分比(P = 0.002)随着细胞学变得更加异常而增加。我们的数据表明,NAF基本上可以在所有符合条件的受试者中获得; ≥95%的NAF样本用于细胞学评估,超过一半的NAF样本用于DNA指数(倍性)和细胞周期分析,可评估乳腺上皮细胞;并且NAF细胞学异常与乳腺癌风险增加相关。这表明在乳头抽吸液中鉴定出的生物标记物可能被证明可作为当前公认的乳腺癌筛查方法的辅助手段,或用于评估对化学预防剂的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号